Co-Diagnostics

Historical price data

Co-Diagnostics is a molecular diagnostics company focused on developing, manufacturing, and marketing tests based on its patented CoPrimer™ technology platform, which aims to improve PCR specificity and sensitivity. The company has commercialized tests for diseases including tuberculosis, hepatitis, HPV, malaria, and SARS-CoV-2, and operates a dual revenue model through direct product sales and IP licensing via its joint venture in India. Its strategy centers on expanding its infectious disease portfolio, growing its global distribution network, and leveraging its platform's flexibility for partnerships and new assay development.

Proprietary CoPrimer™ chemistry for PCR, designed to increase specificity, sensitivity, and resistance to primer-dimer formation, enabling robust detection of nucleic acid targets even with genetic mutations.

Co-Diagnostics competes with large integrated players (Roche, Abbott) and pure-play molecular firms in a crowded market. Its differentiation is based on the claimed performance benefits of its open-platform CoPrimer™ technology and a flexible business model combining product sales and IP licensing.